/NYXH
NYXH Stock - Nyxoah S.A.
Healthcare|Medical - Instruments & SuppliesNASDAQ
$4.85+4.30%
+$0.20 (+4.30%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.10
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.94
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+85.6%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NYXH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.80 – $4.90
TARGET (TP)$9.00
STOP LOSS$4.46
RISK/REWARD1:10.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.65
52W High$11.87
52W Low$4.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.52M | $4.35M | $3.08M | $852,000 | $69,000 |
| Gross Profit | $2.97M | $2.69M | $1.93M | $549,000 | $39,000 |
| Gross Margin | 65.7% | 61.9% | 62.7% | 64.4% | 56.5% |
| Operating Income | $-58,809,000 | $-45,102,000 | $-32,499,000 | $-26,242,000 | $-11,224,000 |
| Net Income | $-59,236,000 | $-43,212,000 | $-31,225,000 | $-27,619,000 | $-12,245,000 |
| Net Margin | -1310.2% | -993.8% | -1012.5% | -3241.7% | -17746.4% |
| EPS | $-1.81 | $-1.55 | $-1.21 | $-1.16 | $-0.68 |
Company Overview
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$26
Average Target
↑ 425.8% Upside
Now
$21
Low
$26
Average
$30
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 31st 2023 | H.C. Wainwright | Initiation | Buy | - |
| July 19th 2023 | Robert W. Baird | Initiation | Neutral | - |
| April 21st 2022 | Oppenheimer | Initiation | Outperform | $30 |
| April 6th 2022 | Wolfe Research | Initiation | Peer Perform | $21 |
Earnings History & Surprises
NYXHBeat Rate
17%
Last 18 quarters
Avg Surprise
-16.8%
EPS vs Estimate
Beats / Misses
3/13
2 met exactly
Latest EPS
$-0.74
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.41vs$-0.41
Q2 24
0.0%
$-0.45vs$-0.45
Q3 24
-2.2%
$-0.46vs$-0.45
Q4 24
-19.6%
$-0.55vs$-0.46
Q1 25
-6.5%
$-0.49vs$-0.46
Q2 25
-28.6%
$-0.63vs$-0.49
Q3 25
-1.6%
$-0.63vs$-0.62
Q4 25
-21.3%
$-0.74vs$-0.61
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.62 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.61 | $-0.74 | -21.3% | ✗ MISS |
Q3 2025 | Aug 18, 2025 | $-0.62 | $-0.63 | -1.6% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.49 | $-0.63 | -28.6% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.46 | $-0.49 | -6.5% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.46 | $-0.55 | -19.6% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.45 | $-0.46 | -2.2% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.45 | $-0.45 | 0.0% | = MET |
Q1 2024 | Mar 5, 2024 | $-0.41 | $-0.41 | 0.0% | = MET |
Q4 2023 | Nov 8, 2023 | $-0.48 | $-0.29 | +39.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.45 | $-0.49 | -8.9% | ✗ MISS |
Q2 2023 | May 16, 2023 | $-0.37 | $-0.49 | -32.4% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-0.28 | $-0.52 | -85.7% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.30 | $-0.24 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.32 | $-0.21 | +34.4% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.26 | $-0.29 | -11.5% | ✗ MISS |
Q1 2022 | Mar 25, 2022 | $-0.27 | $-0.28 | -2.1% | ✗ MISS |
Q4 2021 | Nov 25, 2021 | $-0.23 | $-0.40 | -75.5% | ✗ MISS |
Q3 2021 | Aug 31, 2021 | $-0.19 | $-0.38 | -100.0% | ✗ MISS |
Latest News
Nyxoah Launches Genio System In The Netherlands, Marking First Commercial Implants For Its Breakthrough Obstructive Sleep Apnea Therapy
📈 PositiveBenzinga•Dec 17, 2025, 06:18 AM
Nyxoah Announced That The U.S. Centers For Medicare & Medicaid Services Has Finalized Its CY2026 Hospital Outpatient Prospective Payment System And Ambulatory Surgery Center Rule
➖ NeutralBenzinga•Nov 26, 2025, 08:27 AM
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $9
➖ NeutralBenzinga•Nov 14, 2025, 04:15 PM
Nyxoah Commences Financing Commitment Of Up To $77M
📈 PositiveBenzinga•Nov 13, 2025, 09:45 PM
Nyxoah Q3 EPS $(0.74) Misses $(0.61) Estimate, Sales $2.306M Beat $1.950M Estimate
➖ NeutralBenzinga•Nov 13, 2025, 09:15 PM
Nyxoah shares are trading higher after the company announced it implanted the first U.S. commercial patients with Genio system.
📈 PositiveBenzinga•Oct 6, 2025, 03:03 PM
First US Patients Implanted With Nyxoah's CE-Marked Genio System Signal Strong Demand For Breakthrough Sleep Apnea Therapy
📈 PositiveBenzinga•Oct 6, 2025, 05:59 AM
Nyxoah Announces Continued Expansion Of Commercial Footprint In Middle East, Following First Genio Implant In Abu Dhabi In September 2025
📈 PositiveBenzinga•Sep 23, 2025, 08:12 PM
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems Over Sleep Apnea Device Technology
📉 NegativeBenzinga•Sep 15, 2025, 08:11 PM•Also:
Nyxoah Q2 Revenue Jumps 74 Percent
📈 PositiveThe Motley Fool•Aug 18, 2025, 09:21 PM
Nyxoah Q2 EPS $(0.62) Beats $(0.63) Estimate, Sales $1.519M Miss $1.730M Estimate
➖ NeutralBenzinga•Aug 18, 2025, 08:45 PM
Nyxoah sees Q2 revenue up 73%, plans R&D shift to U.S. and Belgium; shares rise
📈 PositiveSeeking Alpha•Aug 11, 2025, 08:27 AM
Frequently Asked Questions about NYXH
What is NYXH's current stock price?
Nyxoah S.A. (NYXH) is currently trading at $4.85 per share. The stock has moved +4.30% today.
What is the analyst price target for NYXH?
The average analyst price target for NYXH is $9.00, based on 1 analyst.
What sector is Nyxoah S.A. in?
Nyxoah S.A. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is NYXH's market cap?
Nyxoah S.A. has a market capitalization of $0.18 billion, making it a small-cap company.
Does NYXH pay dividends?
No, Nyxoah S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCATX
Perspective Therapeutics, Inc.
$2.75
Mkt Cap: $0.2B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
KRMD
KORU Medical Systems, Inc.
$5.80
Mkt Cap: $0.3B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
OSUR
OraSure Technologies, Inc.
$2.39
Mkt Cap: $0.2B
PRE
Prenetics Global Limited
$17.48
Mkt Cap: $0.2B
STIM
Neuronetics, Inc.
$1.40
Mkt Cap: $0.1B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
UTMD
Utah Medical Products, Inc.
$56.60
Mkt Cap: $0.2B
Explore stocks similar to NYXH for comparison